



Keyword	Abstract Numbers
<b>#</b>	
3D organoid	B015
<b>A</b>	
Adoptive cell therapy	A013
anti-breast cancer activity	B016
anti-PD-1	B009
Apolipoprotein E (ApoE)	B026,PR-01
Autoantibody	PR-12
autoimmunity	B001,PR-10, B015, IA02
<b>B</b>	
B cell infiltration	A010,PR-11
B cells	B007,IA02
Bacterial cancer therapy	IA04
Basophils	A015
BCG immunotherapy	A015, B017,PR-08, B018
BET inhibition	B012
Bladder cancer	A015,B018
breast cancer	B019
<b>C</b>	
Caffeine and Nicotine	B022
cancer	IA02
Cancer immunotherapy	A016, B025, B026,PR-01
Cancer Metastasis	B022
Cancer stem cells	A008
Cancer-associated fibroblasts	IA04
CCR5	B019
CD4 T cells	A008
CD8 T cells	B003
CD8+ T cell response T-cell immunogenicity	B004
cell cycle	B010
CFB	A011,PR-03
cGAS-STING	A022,PR-16
checkpoint immunotherapy	B001,PR-10
Chi3L1	B013
Chordoma	B013
Chronic lymphocytic leukaemia	PR-06
Chronic stress	A014, PR-15
complement	A011,PR-03
compounds	B016
Computational Therapeutic Design	B025
CRISPR	B025
Cutaneous Melanoma	A005



Cytokine	B012
<b>D</b>	
decitabine	IA07
delivery lipid particle aggregate (LPA) and neoepitopes	B004
Dendritic cells	A023,PR-13
DNA damage	IA03
DNA methylation	A006
Drug Delivery and Nanomedicine	B021
<b>E</b>	
endocrine irAEs	IA05
Endogenous retroviruses	PR-04
Epstein-Barr Virus	A006
Extracellular vesicles	A019
<b>G</b>	
Gamma-delta T cells	B006,PR-07
gastrointestinal stromal tumor	B024
GBM	A019
Genetic therapy	B014
Germ cell tumor	B027
glioblastoma	B010, B014
GPCR Signaling	B022
Gut microbiome	B018
Gut microbiota	B017,PR-08
<b>H</b>	
head and neck cancer	B011
Head and Neck Squamous Cell Carcinoma	A020
Her2+ breast cancer GEMM	IA07
Hormone Exposure	B008,PR-14
<b>I</b>	
Imatinib and resistance	B024
Immune checkpoint blockade	A004, A005
Immune checkpoint blockade and Lung Cancer	A017
immune checkpoint inhibitor	B019
Immune microenvironment	A007, A005, B008,PR-14
Immune related adverse events	A002
Immune sensitization	A004
Immune suppression	A014
Immunity	B015
immunoediting	IA07
Immunosignature	B027
	A001, A002, B002,PR-09, B013, IA01,
immunotherapy	IA04
immunotherapy biomarker	B020



Inflammation	A009
innate immunity	A012, A020
Interferon type I	IA03
Intravital microscopy	A010,PR-11
irAEs	B006,PR-07, IA06
<b>K</b>	
KRAS Mutation	A016
<b>L</b>	
leukocyte migration	B001,PR-10
lipid	B024
Lymphoma	A006
<b>M</b>	
macrophages	A012
mast cells	B011
medicinal plant	B016
Melanoma	PR-04
meta-analysis	B002,PR-09
metastasis	B007
microbiome	IA06
mRNA cancer vaccine and RNA	B004
myeloid checkpoints	A023,PR-13
<b>N</b>	
natural killer cell	A016
Natural killer cells	A013
nELISA	B023
Neoantigen	PR-12
neoantigens	B002,PR-09
neurodegenerative disorders	B010
Neuroinflammation	PR-15
Neutrophil extracellular traps	B020
Neutrophil Extracellular Traps and Macrophage	A017
NK cell	A018
NK cells	A012, A019
NOD mouse model	B006,PR-07
Nomic	B023
non-small cell lung cancer	B020
<b>O</b>	
Omni 1000	B023
Oncogenic-Immune Dynamics	A007
Oncolytic virus	B003
Ovarian Cancer	PR-15
Ovarian Cancer and Inflammation	B021
<b>P</b>	



Pancreatic cancer	B003
PAR-2	B009
Phage	B027
Predictive biomarkers	A002
Predictive test	B017,PR-08
PRMT5	PR-04
Prostate Cancer	PR-02
proteomics	A001, A003
PTPN1/PTPN2 inhibition	A018
<b>R</b>	
radiation therapy	IA03
Radioligand Therapy	PR-02
Radiomics	A007
regulatory T cells	IA06
Resistance	A001, A009
RNAseq of T cells	B005
<b>S</b>	
Secondary Hemophagocytic Lymphohistiocytosis	B012
Sex Differences	B008,PR-14
Solid tumors	A013
Squamous cell carcinoma (SCC)	A008
STK11	A011,PR-03
SUMOylation	A021,PR-05
SYNCRIP	B014
Systemic immunosuppression	B026,PR-01
systemic lupus erythematosus	PR-06
<b>T</b>	
target discovery	A003
TCF1	IA02
Tertiary lymphoid structures	A010,PR-11
TEX induced mitochondrial dysfunction	B005
TIM-1	IA01
tissue specific immunotherapy effects	B007
TLR10	A020
TLR-2/4	B021
toxicity	A003
Transmembrane Activator and CAML Interactor	PR-06
Tregs	A023,PR-13
TREX1	A022,PR-16
Tumor cell-derived small extracellular vesicles (TEX)	B005
tumor immune microenvironment	B009
Tumor immune microenvironment	A004
Tumor microenvironment	A014



Tumor Rechallenge	A018
tumor suppression	B011
Tumor-infiltrating B lymphocytes	PR-12
Tumor-on-Chip	A017
Type I interferon	A022,PR-16, PR-02
<b>V</b>	
Viral mimicry	A021,PR-05
<b>Z</b>	
ZBP1	A021,PR-05